The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial-Reference-Cited by-同舟云学术

The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial

Published:2015-03-31 Issue:8 Volume:112 Page:1326-1331
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Algazi A P,Cha E,Ortiz-Urda S M,McCalmont T,Bastian B C,Hwang J,Pampaloni M H,Behr S,Chong K,Cortez B,Quiroz A,Coakley F,Liu S,Daud A I

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2014541.pdf

Reference31 articles.

1. Algazi AP, Soon CW, Daud AI (2010) Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res 2: 197–211.

2. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507–2516.

3. Demirkesen C, Büyükpinarbaşili N, Ramazanoğlu R, Oğuz O, Mandel NM, Kaner G (2006) The correlation of angiogenesis with metastasis in primary cutaneous melanoma: a comparative analysis of microvessel density, expression of vascular endothelial growth factor and basic fibroblastic growth factor. Pathology 38: 132–137.

4. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228–247.

5. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379: 1893–1901.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. VEGF/VEGFR axis and its signaling in melanoma: Current knowledge toward therapeutic targeting agents and future perspectives;Life Sciences;2024-05

2. Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma;Expert Opinion on Pharmacotherapy;2024-03-23

3. Clinicopathological features, current status, and progress of primary central nervous system melanoma diagnosis and treatment;Pigment Cell & Melanoma Research;2023-10-27

4. Combination BRAF^V600E Inhibition with the Multitargeting Tyrosine Kinase Inhibitor Axitinib Shows Additive Anticancer Activity in BRAF^V600E-Mutant Anaplastic Thyroid Cancer;Thyroid®;2023-10-01

5. Advances in targeted therapy and immunotherapy for melanoma (Review);Experimental and Therapeutic Medicine;2023-07-13